![]() The Afinion 2 System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP, and can reliably transfer test information to a HIS or LIS system. Abbott highlighted its Panbio COVID-19 IgG/IgM Rapid Test Device, an in vitro diagnostic rapid test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood, alongside the Panbio COVID-19 Ag Rapid Test Device which can identify potentially contagious patients with or without symptoms in 15 minutes.Īlso on display was the Afinion 2 System, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care for physician offices and clinics, eliminating the need to send patients to the lab or spend time tracking down their results. The easy to use ID NOW platform is designed for near-patient, point-of-care use in a variety of healthcare settings. The ID NOW COVID-19 test returns positive results in 13 minutes or less to enable immediate clinical decisions during the first patient visit. Within its COVID-19 test portfolio, Abbott displayed its ID NOW COVID-19 molecular point-of-care platform that combines the benefits of speed and accuracy for the fastest molecular results in the market. At the 2022 edition of MEDLAB Middle East, Abbott (Lake Forest, IL, USA) showcased its portfolio of life-changing diagnostic tools and medical devices for point-of-care testing that help manage patients with COVID-19, diabetes cardiovascular disease and their comorbidities.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |